|
Gene: TH |
Gene summary for TH |
Gene summary. |
Gene information | Species | Human | Gene symbol | TH | Gene ID | 7054 |
Gene name | tyrosine hydroxylase | |
Gene Alias | DYT14 | |
Cytomap | 11p15.5 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | P07101 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
7054 | TH | C04 | Human | Oral cavity | OSCC | 2.26e-15 | 7.94e-01 | 0.2633 |
7054 | TH | C21 | Human | Oral cavity | OSCC | 3.65e-07 | 1.94e-01 | 0.2678 |
7054 | TH | C30 | Human | Oral cavity | OSCC | 2.87e-17 | 6.63e-01 | 0.3055 |
7054 | TH | C51 | Human | Oral cavity | OSCC | 4.98e-04 | 2.56e-01 | 0.2674 |
7054 | TH | SYSMH5 | Human | Oral cavity | OSCC | 3.73e-03 | 1.34e-01 | 0.0647 |
7054 | TH | P4_cSCC | Human | Skin | cSCC | 3.76e-02 | 9.18e-02 | -0.00290000000000005 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00510289 | Skin | AK | mRNA transport | 26/1910 | 130/18723 | 5.98e-04 | 5.28e-03 | 26 |
GO:190303917 | Skin | AK | positive regulation of leukocyte cell-cell adhesion | 41/1910 | 239/18723 | 6.22e-04 | 5.45e-03 | 41 |
GO:00434899 | Skin | AK | RNA stabilization | 16/1910 | 65/18723 | 6.54e-04 | 5.64e-03 | 16 |
GO:00508031 | Skin | AK | regulation of synapse structure or activity | 38/1910 | 218/18723 | 7.06e-04 | 6.01e-03 | 38 |
GO:00340639 | Skin | AK | stress granule assembly | 9/1910 | 26/18723 | 7.31e-04 | 6.18e-03 | 9 |
GO:00508073 | Skin | AK | regulation of synapse organization | 37/1910 | 211/18723 | 7.35e-04 | 6.20e-03 | 37 |
GO:00456676 | Skin | AK | regulation of osteoblast differentiation | 26/1910 | 132/18723 | 7.61e-04 | 6.39e-03 | 26 |
GO:00481459 | Skin | AK | regulation of fibroblast proliferation | 18/1910 | 80/18723 | 9.77e-04 | 7.78e-03 | 18 |
GO:00481448 | Skin | AK | fibroblast proliferation | 18/1910 | 81/18723 | 1.14e-03 | 8.81e-03 | 18 |
GO:004308716 | Skin | AK | regulation of GTPase activity | 54/1910 | 348/18723 | 1.17e-03 | 8.98e-03 | 54 |
GO:000184116 | Skin | AK | neural tube formation | 21/1910 | 102/18723 | 1.32e-03 | 9.88e-03 | 21 |
GO:00714266 | Skin | AK | ribonucleoprotein complex export from nucleus | 17/1910 | 76/18723 | 1.43e-03 | 1.05e-02 | 17 |
GO:002191510 | Skin | AK | neural tube development | 28/1910 | 152/18723 | 1.44e-03 | 1.06e-02 | 28 |
GO:00303367 | Skin | AK | negative regulation of cell migration | 53/1910 | 344/18723 | 1.52e-03 | 1.10e-02 | 53 |
GO:00610973 | Skin | AK | regulation of protein tyrosine kinase activity | 19/1910 | 90/18723 | 1.61e-03 | 1.15e-02 | 19 |
GO:19020364 | Skin | AK | regulation of hematopoietic stem cell differentiation | 6/1910 | 14/18723 | 1.63e-03 | 1.15e-02 | 6 |
GO:00711666 | Skin | AK | ribonucleoprotein complex localization | 17/1910 | 77/18723 | 1.66e-03 | 1.18e-02 | 17 |
GO:00600715 | Skin | AK | Wnt signaling pathway, planar cell polarity pathway | 13/1910 | 52/18723 | 1.75e-03 | 1.23e-02 | 13 |
GO:00064057 | Skin | AK | RNA export from nucleus | 18/1910 | 84/18723 | 1.77e-03 | 1.23e-02 | 18 |
GO:00507707 | Skin | AK | regulation of axonogenesis | 28/1910 | 154/18723 | 1.77e-03 | 1.23e-02 | 28 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0501230 | Oral cavity | OSCC | Parkinson disease | 188/3704 | 266/8465 | 1.82e-19 | 1.52e-17 | 7.75e-18 | 188 |
hsa05012113 | Oral cavity | OSCC | Parkinson disease | 188/3704 | 266/8465 | 1.82e-19 | 1.52e-17 | 7.75e-18 | 188 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TH | SNV | Missense_Mutation | c.58N>C | p.Glu20Gln | p.E20Q | P07101 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.998) | TCGA-E2-A1LS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cyclophosphamide | SD | |
TH | SNV | Missense_Mutation | novel | c.307N>A | p.Ala103Thr | p.A103T | P07101 | protein_coding | tolerated(0.31) | benign(0.055) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
TH | SNV | Missense_Mutation | rs760640869 | c.374N>T | p.Ser125Leu | p.S125L | P07101 | protein_coding | deleterious(0.01) | benign(0.058) | TCGA-EA-A3QD-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
TH | SNV | Missense_Mutation | c.235N>A | p.Glu79Lys | p.E79K | P07101 | protein_coding | deleterious(0.04) | probably_damaging(0.957) | TCGA-MY-A5BD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
TH | SNV | Missense_Mutation | rs372409517 | c.677N>T | p.Ser226Leu | p.S226L | P07101 | protein_coding | deleterious(0.01) | possibly_damaging(0.661) | TCGA-A6-6780-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
TH | SNV | Missense_Mutation | novel | c.1201N>C | p.Tyr401His | p.Y401H | P07101 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
TH | SNV | Missense_Mutation | novel | c.944N>A | p.Gly315Asp | p.G315D | P07101 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
TH | SNV | Missense_Mutation | rs757607038 | c.806C>T | p.Thr269Met | p.T269M | P07101 | protein_coding | deleterious(0.04) | possibly_damaging(0.904) | TCGA-AA-A022-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TH | SNV | Missense_Mutation | c.721N>A | p.Ala241Thr | p.A241T | P07101 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-F4-6703-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
TH | SNV | Missense_Mutation | rs200751977 | c.1492G>A | p.Asp498Asn | p.D498N | P07101 | protein_coding | deleterious(0.02) | benign(0.077) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
7054 | TH | ENZYME, DRUGGABLE GENOME | L-Phenylalanine | PHENYLALANINE | ||
7054 | TH | ENZYME, DRUGGABLE GENOME | methylphenidate | METHYLPHENIDATE | 26810137 | |
7054 | TH | ENZYME, DRUGGABLE GENOME | metyrosine | METYROSINE | ||
7054 | TH | ENZYME, DRUGGABLE GENOME | EPO | EPOETIN ALFA | 16368081 | |
7054 | TH | ENZYME, DRUGGABLE GENOME | TETRAHYDROBIOPTERIN | SAPROPTERIN | ||
7054 | TH | ENZYME, DRUGGABLE GENOME | SERTRALINE HYDROCHLORIDE | 8629887 | ||
7054 | TH | ENZYME, DRUGGABLE GENOME | DEHYDROEPIANDROSTERONE | PRASTERONE | 8704732 | |
7054 | TH | ENZYME, DRUGGABLE GENOME | inhibitor | CHEMBL1200862 | METYROSINE | |
7054 | TH | ENZYME, DRUGGABLE GENOME | IFN | 8724983 | ||
7054 | TH | ENZYME, DRUGGABLE GENOME | DOXYCYCLINE | DOXYCYCLINE | 15585109 |
Page: 1 2 3 4 |